Skip to content
Yog Pharma
Metabolic and endocrineXanthine oxidase inhibitor (non-purine)

Febuxostat is a xanthine oxidase inhibitor (non-purine) indicated for chronic management of hyperuricemia in adults with gout. We supply it to US manufacturers of tablets.

CAS144060-53-7316.4 g/molC16H16N2O3S
2D structure of Febuxostat.

Data from PubChem (CID 134018) and FDA’s substance registry

CAS number

144060-53-7

Molecular formula

C16H16N2O3S

Molecular weight

316.4g/mol

FDA UNII

IUPAC name

2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid

InChIKey

BQSJTQLCZDPROO-UHFFFAOYSA-N

Appearance
White to off-white, non-hygroscopic crystalline powder.
Solubility
Practically insoluble in water. Freely soluble in dimethylformamide, soluble in dimethyl sulfoxide and sparingly soluble in ethanol.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Known for its many crystal forms. State the polymorph you developed with, and ask how the source controls form through milling and storage.

On the US market

Reference product
UloricNDA 021856
Approved ANDAs
12 with a marketed product
Approved forms and strengths
  • Tablet 40 mg, 80 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com